...
首页> 外文期刊>Cytometry Part B: Clinical Cytometry >Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations
【24h】

Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations

机译:异基因干细胞移植后监测巨细胞病毒IE-1和pp65特异性CD4 + 和CD8 + T细胞反应可能会识别出有CMV复发再发风险的患者 < / sup>

获取原文
获取原文并翻译 | 示例
           

摘要

We studied the recovery of CMV-specific CD4+ and CD8+ T-cell immunity in 52 recipients of allogeneic stem cell transplantation (SCT). The proportions of IFN--producing CD4+ and CD8+ T cells upon in vitro activation using peptide pools representing the CMV pp65 and IE-1 proteins were assessed at multiple time points post SCT, and correlated with the occurrence of CMV reactivation. In a retrospective analysis, recurrent CMV reactivations occurred in 9 patients and were associated with low pp65-specific CD4+ T-cell and low IE-1-specific CD8+ T-cell reactivities, whereas patients without detectable CMV reactivation (n = 30) or a single reactivation (n = 13) showed a better recovery of these immune responses. CD4+ T-cell responses to IE-1 were infrequent in most patients, whereas CD8+ T-cell responses to pp65 occurred frequently, but did not correlate with protection against (recurrent) reactivation. Prospectively, CMV-specific T-cell responses could be studied prior to 14 reactivation episodes in 8 patients. CD4+ T-cell responses to IE-1 and pp65 were positive in only 1 and 2 episodes, respectively. CD8+ T-cell responses against IE-1 were positive in 4, but against pp65 in 12 episodes, again showing that CD8+ T-cell reactivity against pp65 did not prevent CMV reactivation. Thus, monitoring of particular CMV-specific CD4+ and CD8+ T-cell responses after allogeneic SCT may identify patients at risk for recurrent CMV reactivations. © 2008 Clinical Cytometry Society
机译:我们研究了52个异体干细胞移植(SCT)受者中CMV特异性CD4 +和CD8 + T细胞免疫力的恢复。在SCT之后的多个时间点,使用代表CMV pp65和IE-1蛋白的肽库在体外激活后,在产生IFN的CD4 +和CD8 + T细胞中的比例进行了评估,并与CMV重新激活的发生相关。在一项回顾性分析中,有9例患者发生了CMV复发,并与低pp65特异性CD4 + T细胞和IE-1特异性CD8 + T细胞低反应相关,而没有可检测到的CMV活化(n = 30)或单次激活(n = 13)显示这些免疫反应的恢复更好。在大多数患者中,对IE-1的CD4 + T细胞反应很少,而对pp65的CD8 + T细胞反应则频繁发生,但与针对(复发)再激活的保护作用无关。前瞻性地,可以在8位患者中发生14次再激活之前研究CMV特异性T细胞应答。 CD4 + T细胞对IE-1和pp65的反应分别仅在1次和2次发作中呈阳性。针对IE-1的CD8 + T细胞应答在4次中呈阳性,但在12次发作中对pp65呈阳性,再次表明针对pp65的CD8 + T细胞反应性并未阻止CMV重新激活。因此,在同种异体SCT后监测特定的CMV特异性CD4 +和CD8 + T细胞反应可能会识别出存在CMV复发再激活风险的患者。 ©2008临床细胞计数协会

著录项

  • 来源
    《Cytometry Part B: Clinical Cytometry》 |2008年第4期|211-220|共10页
  • 作者单位

    Department of Internal Oncology, Erasmus MC, Rotterdam, The Netherlands;

    Department of Internal Oncology, Erasmus MC, Rotterdam, The Netherlands;

    Department of Trials and Statistics, Erasmus MC, Rotterdam, The Netherlands;

    Laboratory for Histocompatibility and Immunogenetics, Sanquin Blood Bank South West Region, Rotterdam, The Netherlands;

    Department of Virology, Erasmus MC, Rotterdam, The Netherlands;

    Department of Virology, Erasmus MC, Rotterdam, The Netherlands;

    Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;

    Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号